The presence of an oncogenic PI3K mutation has also been correlated with a worse clinical outcome in patients with ABC receiving cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (7). The gene discussed is PIK3CB; the disease is aneurysmal bone cyst.